We are live on ! Find out more
ATOS icon

Atossa Therapeutics

84 hedge funds and large institutions have $17.7M invested in Atossa Therapeutics in 2025 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 14 increasing their positions, 23 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more call options, than puts

Call options by funds: $174K | Put options by funds: $91K

1% more funds holding

Funds holding: 8384 (+1)

4% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 28

0.36% less ownership

Funds ownership: 1.46%1.1% (-0.36%)

7% less capital invested

Capital invested by funds: $19.1M → $17.7M (-$1.36M)

39% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 23

Holders
84
Holders Change
+1
Holders Change %
+1.2%
% of All Funds
1.11%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
29
Increased
14
Reduced
23
Closed
28
Calls
$174K
Puts
$91K
Net Calls
+$83K
Net Calls Change
+$18K

ATOS Hedge Fund Activity: Q2 2025 in Review

84 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2025, worth a combined $17.7M — down 7.2% from $19.1M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ATOS positions and 28 closed out — a net gain of 1 holder — while 14 added to existing stakes and 23 trimmed.

The largest buyer was Ameriprise, opening a new position worth an estimated $2.37M. The largest seller was BlackRock, cutting an estimated $5.96M.

  • 84 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2025, up from 83 in Q1 2025.
  • Funds reported $17.7M of Atossa Therapeutics stock for Q2 2025, down 7.2% quarter-over-quarter.
  • 29 funds opened new Atossa Therapeutics positions in Q2 2025 and 28 closed out, a net change of +1 holder.
  • The largest Atossa Therapeutics buyer in Q2 2025 was Ameriprise, an estimated $2.37M added.
  • The largest Atossa Therapeutics seller in Q2 2025 was BlackRock, an estimated $5.96M sold.

Based on aggregated 13F filings for Q2 2025.